Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection

被引:17
|
作者
Kimbrough, Charles W. [1 ]
Beal, Eliza W. [1 ]
Dillhoff, Mary E. [1 ]
Schmidt, Carl R. [1 ]
Pawlik, Timothy M. [1 ]
Lopez-Aguiar, Alexandra G. [2 ]
Poultsides, George [3 ]
Makris, Eleftherios [3 ]
Rocha, Flavio G. [4 ]
Crown, Angelena [4 ]
Abbott, Daniel E. [5 ]
Fisher, Alexander V. [5 ]
Fields, Ryan C. [6 ]
Krasnick, Bradley A. [6 ]
Idrees, Kamran [7 ]
Marincola-Smith, Paula [7 ]
Cho, Clifford S. [8 ]
Beems, Megan [8 ]
Maithel, Shishir K. [2 ]
Cloyd, Jordan M. [1 ]
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Div Surg Oncol, Columbus, OH 43210 USA
[2] Emory Univ, Dept Surg, Div Surg Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA
[4] Virginia Mason Med Ctr, Dept Surg, Seattle, WA 98101 USA
[5] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA
[6] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[7] Vanderbilt Univ, Dept Surg, Med Ctr, Div Surg Oncol, Nashville, TN 37240 USA
[8] Univ Michigan, Dept Surg, Div Hepatopancreatobiliary & Adv Gastrointestinal, Ann Arbor, MI 48109 USA
关键词
GASTROINTESTINAL CARCINOIDS; PANCREAS; SURGERY; ORIGIN;
D O I
10.1016/j.surg.2018.09.008
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The incidence, clinical characteristics, and long-term outcomes of patients with gastroenteropancreatic neuroendrocrine tumors and carcinoid syndrome undergoing operative resection have not been well characterized. Methods: Patients undergoing resection of primary or metastatic gastroenteropancreatic neuroendrocrine tumors between 2000 and 2016 were identified from an 8-institution collaborative database. Clinicopathologic and postoperative characteristics as well as overall survival and disease-free survival were compared among patients with and without carcinoid syndrome. Results: Among 2,182 patients who underwent resection, 139 (6.4%) had preoperative carcinoid syndrome. Patients with carcinoid syndrome were more likely to have midgut primary tumors (44.6% vs 21.4%, P < .001), lymph node metastasis (63.4% vs 44.3%, P < .001), and metastatic disease (62.8% vs 26.7%, P < .001). There was no difference in tumor differentiation, grade, or Ki67 status. Perioperative carcinoid crisis was rare (1.6% vs 0%, P < .01), and the presence of preoperative carcinoid syndrome was not associated with postoperative morbidity (38.8% vs 45.5%, P = .129). Substantial symptom improvement was reported in 59.5% of patients who underwent curative-intent resection, but occurred in only 22.7% who underwent debulking. Despite an association on univariate analysis (P = .04), carcinoid syndrome was not independently associated with disease-free survival after controlling for confounding factors (hazard ratio 0.97, 95% confidence interval 0.64-1.45). Preoperative carcinoid syndrome was not associated with overall survival on univariate or multivariate analysis. Conclusion: Among patients undergoing operative resection of gastroenteropancreatic neuroendrocrine tumors, the prevalence of preoperative carcinoid syndrome was low. Although operative intervention with resection or especially debulking in patients with carcinoid syndrome was disappointing and often failed to improve symptoms, after controlling for markers of tumor burden, carcinoid syndrome was not independently associated with worse disease-free survival or overall survival. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 50 条
  • [21] Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors
    Cai, Beilei
    Broder, Michael S.
    Chang, Eunice
    Yan, Tingjian
    Metz, David C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (40) : 7283 - 7291
  • [22] Characteristics and clinical presentation of primary cardiac tumors in patients undergoing surgical resection
    Franzosi, Cinzia Bianca Laura
    Matteo, Federica
    Ferrarese, Sandro
    Massimi, Giulio
    Matteucci, Matteo
    Asta, Claudio
    Beghi, Cesare
    De Ponti, Roberto
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0J) : J181 - J181
  • [23] Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors
    Lebtahi, R
    Cadiot, G
    Sarda, L
    Daou, D
    Faraggi, M
    Petegnief, Y
    Mignon, M
    LeGuludec, D
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (06) : 853 - 858
  • [24] Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Hasegawa, Sho
    Kobayashi, Noritoshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Takano, Shoko
    Takada, Yuuki
    Kaneta, Tomohiro
    Mori, Ryutaro
    Matsuyama, Ryusei
    Endo, Itaru
    Yamanaka, Shoji
    Nakajima, Atsushi
    Inoue, Tomio
    Ichikawa, Yasushi
    DIGESTION, 2017, 96 (01) : 13 - 20
  • [25] Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
    Carrillo, D.
    Munoz-Anguita, G.
    Madison, A.
    Retamal, I
    Pinto, M.
    Bravo, L.
    Cordova Delgado, M.
    Munoz-Medel, M.
    Garrido, M.
    NEUROENDOCRINOLOGY, 2020, 110 : 65 - 65
  • [26] Clinical Characteristics and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience in China
    Hu, Han-kui
    Ke, Neng-wen
    Li, Ang
    Du, Xiao-jiong
    Guo, Qiang
    Hu, Wei-ming
    HEPATO-GASTROENTEROLOGY, 2015, 62 (137) : 178 - 183
  • [27] Does Adjuvant Therapy Following Resection of Gastroenteropancreatic Neuroendocrine Tumors Improve Outcomes? An Analysis of the US Neuroendocrine Tumor Study Group
    Barrett, J.
    Lopez-Aguiar, A. G.
    Poultsides, G.
    Rocha, F.
    Crown, A.
    Pawlik, T.
    Fields, R.
    Panni, R. Z.
    Idrees, K.
    Cho, C. S.
    Fisher, A.
    Weber, S.
    Maithel, S.
    Abbott, D.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S152 - S153
  • [28] Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States
    Jiao, Xiaolong
    Pulgar, Sonia
    Boyd, Marley
    Braiteh, Fadi
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Fox, Patricia
    Frytak, Jennifer
    Cox, David
    Paulson, A. Scott
    PANCREAS, 2018, 47 (02) : 173 - 182
  • [29] Recurrence Patterns Following Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: An Analysis From the NCCN Oncology Outcomes Database
    Van Loon, Katherine
    Zhang, Li
    Creasman, Jennifer
    Bobiak, Sarah
    Zornosa, Carrie C.
    Choti, Michael A.
    Kulke, Matthew
    Yao, James C.
    Nakakura, Eric K.
    Bloomston, Mark
    Benson, Al B.
    Shah, Manisha H.
    Strosberg, Jonathan R.
    Bergsland, Emily K.
    PANCREAS, 2016, 45 (03) : 484 - 484
  • [30] Recurrence following surgical resection of gastroenteropancreatic neuroendocrine tumors (NETs): An analysis from the NCCN oncology outcomes database
    Van Loon, Katherine
    Zhang, Li
    Creasman, Jennifer M.
    Choti, Michael A.
    Yao, James C.
    Kulke, Matthew H.
    Nakakura, Eric K.
    Bloomston, Mark
    Benson, Al Bowen
    Shah, Manisha H.
    Strosberg, Jonathan R.
    Zornosa, Carrie C.
    Bobiak, Sarah
    Bergsland, Emily K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)